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Abstract 
Background: Plasmodium falciparum drug resistance surveillance is key to successful disease control and eradication. 
Contemporary methods that only allow determination of prevalence of resistance are expensive, time consuming 
and require ethical considerations. A newer method involving Next Generation Sequencing (NGS) permits obtaining 
frequency of resistance while allowing to detect minority variants in mixed infections. Here, NGS was tested for P. falci-
parum resistance marker detection in mosquito samples as a feasible and suitable alternative for molecular resistance 
surveillance. Anopheles funestus were collected in southern Mozambique using CDC light traps and manual collec‑
tions. DNA was extracted from either whole mosquito, head‑thorax and abdomen separately or pools of five mosqui‑
toes. These samples were screened for P. falciparum and if positive for k13, pfcrt, pfmdr1, pfdhps and pfdhfr mutations 
related to anti‑malarial drug resistance with Sanger sequencing and NGS.
Results: Among the 846 samples screened for P. falciparum, 122 were positive by 18S ssrDNA qPCR with an infection 
rate of 23.6%. No mutations were observed for k13 and pfcrt72‑76 and almost zero for pfmdr86, but quintuple pfdhfr/
pfdhps mutations were near fixation and about half of the isolates contained the pfmdr184F polymorphism. Similar 
allele frequencies of resistance markers were estimated with NGS in comparison with the prevalence of markers 
obtained with the gold standard Sanger sequencing.
Conclusions: Pooled deep sequencing of P. falciparum isolates extracted from mosquitoes is a promising, efficient 
and cost‑effective method to quantify allele frequencies at population level which allows to detect known and 
unknown markers of resistance in single and mixed infections in a timelier manner. Using mosquitoes as sentinel 
group and focusing on allele frequency opposed to prevalence, permits active surveillance across a more homogene‑
ous geographical range.
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Background
Currently, most malaria control programmes include 
vector control, early diagnosis and effective treatment 
of clinical cases [1]. However, Plasmodium falciparum 
resistance to anti-malarial drugs is one of the main chal-
lenges for malaria control in endemic countries since 
resistant parasites are widespread and continue to evolve 
in response to the selective pressure applied [2–5]. Chlo-
roquine (CQ) and sulfadoxine–pyrimethamine (SP) had 
to be discontinued for clinical malaria treatment follow-
ing increased morbidity and mortality associated with 
resistance in the past decades. The same could happen in 
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the near future to artemisinin-based combination ther-
apy (ACT), the current first-line therapy, if an alternative 
would be available [4–8]. Resistance to CQ and SP arose 
in South-East (SE) Asia and spread to Africa [9–11]. 
Similarly, concern about the possible expansion or emer-
gence of resistance to artemisinin or to its partner drug in 
the ACT in Africa has been raised due to parasites with 
increased clearance time spreading throughout SE Asia 
[5, 9, 10, 12, 13]. Due to lack of an alternative anti-malar-
ial drug with the same level of efficacy and tolerability at 
present and in order to achieve successful disease con-
trol and eradication, it is fundamental to understand the 
prevalence and geographical distribution of drug resist-
ance. This requires (1) having up-to-date information on 
efficacy of these therapies in different areas, (2) establish-
ing an early intervention system and (3) understanding 
more about the principles of spread of resistance in dif-
ferent areas [2, 3, 14].
Resistance surveillance may be done in several different 
ways: in  vivo, ex  vivo/in vitro and by mapping molecu-
lar markers [5, 15]. In vivo studies, such as drug efficacy 
trials, are the gold standard [7, 16, 17] where resistance 
is characterized by treatment failure or delayed parasite 
clearance in patients [4, 16, 18]. They are relatively easy 
to standardize and do not require complex equipment 
[5]. However, drug efficacy trials are difficult to carry out 
due to the need of patient follow up (at least 28 days or 
42–63  days for drugs with longer half-lives), financial 
costs, ethical clearance processes and the added logis-
tical challenges in low transmission settings, such as a 
small number of people in treatment [3, 5, 17]. In ex vivo/
in vitro resistance studies, parasites are extracted from 
human blood, grown in culture and exposed to drugs [5, 
15]. These studies provide remarkable information on the 
parasite’s susceptibility, which is defined by measuring 
growth or replication in the presence of different con-
centrations of these anti-malarial drugs [5, 15, 17]. Their 
main advantage is that they allow to gather information 
on drug susceptibility to individual drugs while avoiding 
the confounding effects of in  vivo studies, such as host 
immunity or pharmacokinetics [15, 17]. However, ex vivo 
studies often present difficulties in the comparison of 
data between different laboratories due to variations 
among protocols and different criteria when accepting 
or rejecting data, as its interpretation is mainly based on 
visual inspection of dose–response curves [15].
Finally, studies of molecular markers of resistance in 
parasites from human blood samples are the most com-
monly used for resistance surveillance. These methods 
are reliable, timely, cost-effective, quantitative and scal-
able [3, 5, 16]. Moreover, they are relatively easy to imple-
ment and interpret and provide useful information on 
the spread of known resistance markers [5, 17]. Although 
the presence of these resistance markers is linked to an 
increased treatment failure, extrapolation to in vivo ther-
apeutic [5, 16, 17, 19] and preventive [20] efficacy is still 
challenging, added to a lack of methodological stand-
ardization [17]. In addition, both ex vivo and molecular 
markers studies require trained personnel and specialized 
laboratory facilities [5, 17], although these facilities are 
becoming more common in malaria endemic countries. 
A limiting step in all of the above mentioned surveillance 
strategies is that they are dependent on participation and 
blood sampling of human subjects. Hence the develop-
ment and execution of such studies may be expensive, 
time consuming and need to be ethically justified. Con-
sequently, there are typically a relatively small number of 
well-studied sites in endemic areas due to logistical and 
financial limitations [4].
However, the parasite’s life cycle involves the succes-
sive infection of another host besides humans: female 
Anopheline mosquitoes. The collection of these vec-
tors does not require complex and invasive tools, medi-
cal training or ethical considerations and it has been 
shown that mosquito stage malaria parasites are use-
ful to perform drug-resistance epidemiological studies 
[21]. Hence, a more cost-effective alternative to genetic 
screening of parasites in human blood would be to screen 
these parasites inside their vector to identify and detect 
the prevalence of resistant mutants in malaria endemic 
areas by mapping molecular markers of resistance [3, 7, 
22].
Molecular genotyping techniques have been shown to 
be useful in epidemiological monitoring of resistant P. 
falciparum present in the vectors [22, 23]. PCR–RFLP 
(polymerase chain reaction–restriction fragment length 
polymorphism), the traditional molecular genotyping 
technique for monitoring drug resistance, while rela-
tively easy, economic [24] and fast [7] compared to other 
molecular techniques, does not allow for the discovery of 
novel genetic polymorphisms since it targets predefined 
polymorphisms [5, 25]. Furthermore, it has relatively low 
sensitivity and may lead to results that cannot be directly 
compared between studies due to different fragment siz-
ing that can be obtained from the same molecular marker 
[5, 7, 16, 24, 25]. Sanger sequencing, a newer method and 
the gold standard, facilitates this, but its application to 
large-scale surveillance is limited by low throughput; its 
reagents relatively higher costs, which are directly pro-
portional to the number of specimens genotyped; and 
the inability to detect polymorphisms at minor frequen-
cies especially in high transmission areas [3, 5, 16]. Next 
Generation Deep Sequencing (NGS) is the latest tech-
nique. Although it requires trained staff [17], as all other 
molecular techniques, it can potentially overcome most 
drawbacks of other molecular genotyping methods and 
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allow detection of novel mutations and minority variant 
genotypes in mixed infections and quantification of allele 
frequencies in mixed genotypes, which are usually classi-
fied as mutant and, therefore, avoid neglecting the pres-
ence of wild-type parasites [3, 5, 26–28].
Moreover, it permits higher throughput, sensitivity, 
resolution and scalability by pooling all samples, allowing 
gathering data on the frequency of resistance alleles in a 
certain area [16, 17, 28]. It is, therefore, important to con-
sider whether the most relevant resistance data is on the 
level of prevalence of resistance (number of individuals 
infected with a parasite containing resistance marker) or 
overall allele frequency. To understand the evolutionary 
dynamics, allele frequencies need to be assessed in order 
to determine how fast an allele is spreading through a 
population. Standard surveillance techniques do not 
allow to obtain information on frequency of resistance 
alleles in the parasite population. However, NGS has 
been identified as a method to determine resistant allele 
frequencies in a population [3] and can potentially bene-
fit the identification of circulating drug-resistant alleles of 
individual parasites before they are even selected by drug 
pressure [17, 26].
Here, the aim was to test whether NGS for P. falcipa-
rum resistance marker detection in mosquito samples is 
feasible and if it is a suitable, economic and high-through-
put alternative for molecular resistance surveillance.
Methods
Mosquito collection
Anopheles spp. mosquitoes were collected indoors in 
thatched and metal roof houses in March 2016 in the 
town of Palmeira (Manhiça district; S 25°16′40.058″, E 
32°52′9.076″), in the South of Mozambique (Fig. 1). It fea-
tures a tropical savannah climate and exhibits a relatively 
high malaria transmission (between 100 and 200 cases 
per 1000 population) [29] although transmission rates 
have still decreased dramatically in the past decade [30]. 
Two collection methods were used: early-morning man-
ual collection by mouth aspiration and overnight collec-
tion with New Standard Miniature Incandescent Light 
Trap Model 1012 (John W Hock, USA). In brief, early-
morning collections were performed by a manual mouth 
aspirator whereby female mosquitoes from the Anophe-
line genus were aspirated and transferred to a cup. Min-
iature light traps were hung next to occupants sleeping 
under insecticide-treated bed nets (LLINs) and emptied 
the next morning. Early morning collections and min-
iature light trap collections were not performed in the 
same house. Mosquitoes from both collections were sub-
sequently killed in the freezer and stored in tubes with 
silica gel to desiccate. Afterwards, mosquitoes were mor-
phologically identified to species by trained microsco-
pists using keys of Gillies and Coetzee [31]. The majority 
of the mosquitoes were identified microscopically as part 
of the An. funestus species complex (99.5%), as found 
alongside in other studies in the south of Mozambique 
[32] and considered to be a major human malaria vector 
in Africa [33]. Therefore, they were the mosquitoes cho-
sen to include in this study, other Anopheles species were 
excluded.
DNA extraction
DNA extraction from An. funestus mosquitoes was car-
ried out using a  DNeasy® Blood & Tissue Kit (QIAGEN, 
Netherlands) following the manufacturer’s instructions 
Fig. 1 Location of the mosquito collection site
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for tissue extraction. In brief: mosquitoes were grinded 
in a lysis buffer and subsequently incubated for a mini-
mum of three hours up to overnight at 56  °C. Lysed 
samples were subsequently transferred to spin columns 
and extraction proceeded according to manufacturer’s 
instructions. Three different DNA extraction meth-
ods were compared: (1) DNA was extracted from whole 
mosquito, (2) mosquitoes were bisected and DNA was 
extracted from head/thorax (sporozoites only, either in 
salivary glands and/or circulating in haemolymph) and 
abdomen (all stages) separately [34–36], and (3) groups of 
five whole mosquitoes were pooled and grinded into one 
single sample and DNA was extracted from this mixture.
Real‑time quantitative polymerase chain reaction (qPCR)
Following DNA extraction, real-time quantitative PCR 
(qPCR) to amplify the 18S small sub-unit rRNA gen 
(ssrDNA) of P. falciparum was carried out on an 7500 
Real-Time PCR System (Applied Biosystems, USA) as 
described in [37] with minor changes. Briefly, a PCR mix-
ture was prepared with 2.5 µl of DNA template, a 5 µM 
concentration of each primer and a 1.5  µM concentra-
tion of  TaqMan® TAMRA Probe labelled with 6-carboxy-
fluorescein (FAM) as a reporter. A standard curve was 
prepared using 3D7 samples with a known concentration 
of parasites and it was run in triplicate with five serially 
diluted points for each PCR 96 well plate. The results 
were analysed using default settings on the Applied Bio-
systems 7500 Fast Real-Time PCR System Sequence 
Detection Software v1.4.1. P. falciparum positive samples 
were selected for sequencing.
Mutation frequencies estimation by Sanger sequencing
Five genes were prepared for sequencing to assess muta-
tion frequencies using Sanger and NGS: P. falciparum k13 
propeller gene, chloroquine resistance transporter (pfcrt), 
multidrug resistance (pfmdr1) gene, dihydropteroate syn-
thase (pfdhps) and dihydrofolate reductase (pfdhfr).
DNA templates positive by qPCR were amplified on a 
2720 Thermal Cycler (Applied Biosystems, USA) follow-
ing protocols described elsewhere [3, 23, 36, 38, 39]. K13 
propeller gene primers were taken from [36]; pfdhfr from 
[3, 38]; and pfdhps from [3] and nested reverse primer for 
pfdhps fragment 1 and nested forward primer for pfdhps 
fragment 2 were newly designed for this purpose with a 
similar melting temperature (Tm) to those from [3] and 
GC percentage around 40%. Primers for pfcrt were previ-
ously described in [39] and for pfmdr1 in [23] (see Addi-
tional file 1: Table S1).
Known positive controls for k13 propeller gene (k13_1, 
k13_2, k13_3, k13_4, k13_5 and k13_6) provided by the 
Institut Pasteur in Cambodia, parasite lines with known 
pfcrt and pfmdr1 alleles (3D7, 7G8, Dd2 and V1/S) and 
plasmids with known pfdhps and pfdhfr alleles (DHPS-
V1S, DHPS-PERU, DHPS-MALI, DHPS-DD2, DHFR-
V1S, DHFR-FCB, DHFR-50 and DHFR-3D7) were also 
amplified and sequenced simultaneously with the rest of 
the samples.
PCR products were run on 2% agarose gels in order 
to confirm correct amplification. TrackIt™ 100  bp DNA 
Ladder Invitrogen™ Life Technologies™ was used to size 
DNA fragments for each amplified gene.
Sanger sequencing of P. falciparum k13, pfcrt, pfmdr1, 
pfdhps and pfdhfr genes of those samples with cor-
rectly amplified DNA was performed as described else-
where [23]. K13 propeller gene primers were taken from 
[36]; pfdhfr from [38]; and pfdhps from [3] and reverse 
primer for pfdhps fragment 1 and forward primer for 
pfdhps fragment 2 were newly designed for this pur-
pose in order to meet  Genewiz® requirements and with 
a similar Tm to those from [3]. Primers for pfcrt were 
previously described in [39] and for pfmdr1 in [23] (see 
Additional file 1: Table S2). Sequencing was carried out 
by  Genewiz® and results were manually inspected with 
BioEdit Sequence Alignment Editor v7.0.5 using Plas-
moDB reference sequences for all the genes of interest: 
k13 (PF3D7_1343700), pfcrt (PF3D7_0709000), pfmdr1 
(PF3D7_0523000), pfdhps (PF3D7_0810800) and pfdhfr 
(PF3D7_0417200) [40].
Validation of Next Generation Sequencing (NGS) method
Since amplification intensity appeared similar among 
samples based on visual inspection of band brightness, 
10 µl of each PCR product was taken for pooling. 2% aga-
rose gels were run in order to obtain clear bands which 
could be purified using  QIAquick® Gel Extraction Kit 
(QIAGEN, Netherlands) following the manufacturer’s 
instructions. Briefly, samples were incubated at 55 °C for 
20  min and then applied to spin columns. Finally, col-
umns were incubated with the elution buffer for 10 min 
before final elution. This same procedure was followed 
for 3D7 amplified for all genes as a control.
Qubit quantification of the eluted DNA was performed. 
Equimolar pooling of gene amplicons to a molarity higher 
than 4 nM was prepared for each pool: field samples and 
3D7 control. In the core genomics facility IDIBAPS (August 
Pi i Sunyer Biomedical Research Institute), a Nextera DNA 
library was prepared for both tubes and their size and con-
centration were checked with 4200 TapeStation Instru-
ment (Aligent, USA) and KAPA Library Quantification 
Kit  Illumina® Platforms (Roche, USA), respectively. After, 
NGS was performed in duplicate for each of the tubes also 
by IDIPABS on the  MiSeq® System (Illumina, USA) (see 
Additional file 1: Figure S1).
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Data analysis
Fisher’s exact test was performed to determine correla-
tion between head/thorax and abdomen positivity rate. 
χ-squared test and Fisher’s exact test were calculated to 
compare the number of positive mosquitoes for each 
extraction method (whole body, bisected and pooled) and 
per collection method (miniature light traps or mouth aspi-
rator). Parasite density (number of parasites per sample) 
was log-transformed to meet normality assumptions. The 
geometric mean parasite density and standard deviation 
(including Taylor’s expansion) were determined. Welch two 
sample t-test and analysis of variance (one way ANOVA) 
were conducted to analyse parasite density (number of 
parasites per sample) for each collection and extraction 
method, respectively. Statistical analyses were performed 
using R version 3.3.2 [41]. Twenty-four samples of the man-
ual collected mosquitoes were excluded from infection rate 
calculations (12 head/thorax, 12 abdomen) due to an error 
in the extraction procedure, which could have impacted P. 
falciparum detection probability.
Mutation prevalence obtained by Sanger sequencing 
analysis were calculated for each gene and per position 
based on the number of samples called by the software 
as wild-type or mutant alleles. Out of these, mixed alleles 
were visually observed in the chromatogram. Sequences 
were also screened for novel mutations.
Each NGS run replicate was analysed independently on 
Ubuntu, a Linux distribution. First, data quality control was 
carried out using the program FastQC version 3.3.2 [42]. 
Since the sequences analysed presented good quality, sub-
sequent sequence alignment was accomplished using the 
program Bowtie2 version 2.3.4 using default settings and 
the software Genome Browse Golden Helix v2 was used to 
view the alignments [43, 44]. Depth of coverage was calcu-
lated using the following formula:
Finally, variant calling against P. falciparum 3D7 ref-
erence sequence from PlasmoDB and quality filtration 
were performed using GATK 3.8.1 and Picard Tools 4.0.1 
(see Additional file 1: Figure S1) [45]. Phred quality score 
during variant calling was set to 20, to allow for a base 
call accuracy of 99%, which has been shown to provide 
accurate results [26, 27, 45–50]. Filtering thresholds were 
set as recommended by the software developers, which 
allowed to prioritize sensitivity over specificity [45]. 
Those variants which passed all the filters were included 
in further allele frequency analyses. PCR duplicates were 
not removed as it does not provide downstream added 
insight in exome sequencing [45]. Allele frequency esti-
mates were calculated by dividing individual unfiltered 
allele depth by total filtered depth, hence total values do 
coverage =
number of aligned reads× length of reads
total size of the sample sequence
not always add up to 100 [45]. FDR was calculated using 
Benjamini–Hochberg Procedure. χ-squared test and 
Fisher’s exact test were calculated to compare the fre-
quency and prevalence of wild-type and mutant alleles 
for both sequencing techniques.
Results
Mosquito infection rate
A total of 995 mosquitoes were collected (429 by mouth 
aspirator and 566 by miniature light traps). Of those, 846 
were screened for P. falciparum by qPCR (429 from man-
ual collections and 417 from miniature light traps). Out 
of these, 122 samples were qPCR-positive, two of which 
were excluded from the infection rate calculations due to 
an error in the extraction procedure as precaution, but 
were included in Sanger and NGS analyses (see Table 1). 
Infection rate for whole mosquito was 23.6%. Infection 
rates for head/thorax and abdomen portions separately 
were lower, 6% and 18.3%, respectively. Moreover, P. fal-
ciparum detection in a mosquito head/thorax portion 
was correlated with P. falciparum detection in the abdo-
men of the same specimen (p < 0.001). Positivity rate for 
pooled samples was 16.7%.
More samples positive for P. falciparum were col-
lected with the miniature light traps than with the man-
ual collection methods (Table  1): head/thorax portions 
(8.7% vs. 3.3%, p = 0.05), mosquito abdomens (24.0% vs. 
12.7%, p = 0.02) and pools of mosquitoes (28.2% vs. 5.1%, 
p = 0.01). Yet frequency of P. falciparum detection in the 
mosquito as a whole was similar between miniature light 
trap collected mosquitoes and manual collections (29.2% 
vs. 18.1%, p = 0.2).
The geometric mean parasite density (number of par-
asites per sample) was 42.1 with a standard deviation 
of 76.8. There was no statistically significant difference 
between the parasite density of mosquitoes in the two 
collection methods (miniature light traps and mouth 
aspirator) (t = 0.7, df = 74.1, p = 0.5), and neither was 
Table 1 Number of  P. falciparum positive mosquitoes (n) 
per total tested (N) by qPCR captured with miniature light 
traps and mouth aspirator from each sample type
CDC light 
traps
n/N (%)
Mouth 
aspiration 
(manual)
n/N (%)
Total n/N (%) p‑value
Whole body 21/72 (29.2) 13/72 (18.1) 34/144 (23.6) 0.2
Head/thorax 13/150 (8.7) 5/150 (3.3) 18/300 (6) 0.05
Abdomen 36/150 (24.0) 19/150 (12.7) 55/300 (18.3) 0.02
Pooled 11/39 (28.2) 2/39 (5.1) 3/78 (16.7) 0.01
Total 81/411 (19.7) 39/411 (9.5) 120/822 (14.6)
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there between extraction methods (whole body, bisection 
and pooled)  (F3,118 = 1.5, p = 0.2) (Table 2).
Allele prevalence estimation using Sanger sequencing
122 samples were positive for P. falciparum; out of which 
successfully sequenced sample numbers (forward and/
or reverse) per gene were 66 for k13 (54.1%), 93 for pfcrt 
(76.2%), 81 for pfmdr1 fragment 1 (66.4%), 70 for pfmdr1 
fragment 2 (57.4%), 86 for pfdhps fragment 1 (70.5%), 87 
for pfdhps fragment 2 (71.3%) and 95 for pfdhfr (77.9%) 
(Sequencing success rate per gene and extraction method 
and per position can be found in Additional file 1: Tables 
S3 and S4, respectively). Unsuccessful sequencing was 
correlated with low parasite numbers (72.7% of these 
samples presented a density below 10 parasites/µl). No 
amplification was observed in the negative controls.
No significant difference was detected in resistance 
allele prevalence by extraction and collection meth-
ods, therefore these data were pooled together and 
allele prevalence was calculated for each gene and per 
locus (Table  3, Additional file  1: Table  S5). Novel poly-
morphisms were detected in pfmdr1 positions T1069T 
(derived from a T → G nucleotide change; in 4 out of 
70 samples), T1071V (derived from an A → G nucleo-
tide change; in 1 out of 70 samples) and S1075N (derived 
from a G → A nucleotide change; in 1 out of 70 sam-
ples) and in k13 position S624L (derived from a C → T 
nucleotide change; in 1 out of 66 samples). An interesting 
side observation was that the control parasite line Dd2 
for pfmdr1 showed a mutation in position N86F, which 
derives from an A → T nucleotide change from N86Y, as 
previously reported by a different laboratory [24].
Allele frequencies estimation using Next Generation 
Sequencing (NGS)
Deep sequencing returned between 2,273,242 and 
112,206 reads depending on the fragment analysed. 
However, after SNP calling and filtering, confident num-
ber of reads was between 115,477 and 2,255,289 with a 
geometric mean of 299,566. False discovery rate (FDR) 
of NGS calculated using Benjamini–Hochberg proce-
dure was below 1%. 3D7 control base calling returned 
as expected except for some point mutations in pfdhps 
(see Additional file  1: Table  S6). However, conserva-
tive regions surrounding well-known polymorphisms 
remained unchanged, giving confidence in the SNPs 
observed from the mosquito samples. Estimated wild-
type and mutant allele frequencies per gene and per 
position are represented in Table 3 and Additional file 1: 
Table S7.
Comparison of Sanger and NGS methods
Most of allele frequencies obtained by NGS were similar 
if not identical to allele prevalence obtained by Sanger 
sequencing although, in general, a higher number of 
wild-type alleles were detected with NGS (Table 3). Nev-
ertheless, three positions of three different genes had 
statistically significant different results when comparing 
both sequencing techniques: pfmdr1 position N86Y/F, 
pfdhps position A437G and pfdhfr position C50R/S. 
These results were due to the appearance of one or two 
observations by Sanger while none by NGS (Additional 
file 1: Table S7). Visual inspection of the raw sequencing 
reads did reveal these mutations but the variant calling 
software filtered these out.
Discussion
Here, using a Next Generation Sequencing platform, 
mutant allele frequencies were obtained of P. falcipa-
rum parasites isolated from mosquitoes from southern 
Mozambique. Similar allele frequencies of resistance 
markers were found with NGS compared to the preva-
lence of markers obtained with the gold standard Sanger 
sequencing. These resistance data obtained from mosqui-
toes involved a simpler and non-invasive sample collec-
tion, and the NGS approach allowed for high-throughput 
analyses leading to epidemiologically more relevant 
allele frequencies as opposed to resistance prevalence. 
Table 2 Geometric mean parasite density (number of  parasites per  mosquito) and  standard deviation of  positive 
mosquitoes tested by qPCR captured with CDC light traps and mouth aspirator from either whole body DNA extraction, 
head/thorax and abdomen separately or in a pool of five mosquitoes
CDC light traps Mouth aspiration (manual) Total
Mean Standard deviation Mean Standard deviation Mean Standard 
deviation
Whole body 40.6 54.3 40.6 87.9 40.6 67.8
Head/thorax 12.3 16.4 57.6 113.2 18.9 30.9
Abdomen 72.3 135.0 29.4 57.7 51.9 100.5
Pooled 59.1 119.5 38.6 0.4 55.3 102.5
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Therefore, this mosquito-based NGS approach is a valu-
able drug resistance marker surveillance tool to fill in the 
large geographical gaps in resistance surveillance.
Both Sanger and NGS reflected 100% of prevalence of 
the wild-type allele of the k13 propeller gene in positions 
Y493H, R539T, I543T and C580Y, polymorphisms associ-
ated with artemisinin resistance [36]. This finding along 
with other studies supports the notion that artemisinin-
driven selection on the k13 locus is still absent in Africa 
[23, 36]. However, Sanger sequencing revealed one not 
yet described polymorphism on the k13 gene in one of 
the head/thorax samples in position S624L. Although the 
relevance of this single observation is uncertain, it has 
been shown that new point mutations frequently appear 
worldwide in the k13 locus [36, 51–54] and, even though 
not being strongly selected at this time outside SE Asia, 
they have the potential to enable resistance to rapidly 
emerge in the future [13, 55]. Particularly with the recent 
observations of an independent emergence of the C580Y 
point mutation in Guyana [56] and the reporting of an 
artemisinin-resistant P. falciparum with a previously 
unreported SNP in position M579I contracted in Equa-
torial Guinea [54], k13 molecular surveillance is of criti-
cal importance. With newly arising mutations starting 
at low frequencies in a population, allele frequency esti-
mates, rather than prevalence estimates, are more reli-
able [36, 57]. This study further confirmed the decades 
long increase of wild-type pfcrt parasites in the area [23, 
39], with no mutations at all observed on this locus com-
pared to 85% presence of K76T mutation in 1999 [58]. As 
previously observed by Gupta and colleagues [23], Sanger 
sequencing analyses of pfmdr1 revealed that more than 
half (53.1%) of the positive for P. falciparum mosquitoes 
tested exhibited Y184F mutation, including 32% of the 
total that accounts for mixed (wild-type and mutant) 
infections. NGS analyses were very similar with 49.3% 
frequency of this same point mutation. Furthermore, 
new possible point mutations appeared during Sanger 
sequencing analyses of pfmdr1 in positions T1069T, 
T1071V and S1075N in five different mosquito abdo-
men samples. Positions T1071V and S1075N have not 
been previously described and were polymorphic in only 
Table 3 Comparison of wild type and mutant frequencies of P. falciparum in mosquito samples using Sanger sequencing 
and NGS
Fisher’s exact test was utilized for all comparisons except for pfmdr1 position Y184F, for which χ‑squared test was performed. Sanger sequencing mixtures were 
assumed as mutant for statistical calculations. F1: fragment 1. F2: fragment 2. Wild‑type haplotypes are indicated on the left and mutant amino acids on the right of 
the position number (see Additional file 1: Tables S5 and S7)
a NGS allele frequency estimates were calculated by dividing individual unfiltered allele depth by total filtered depth, hence total values do not always add up to 100 
(see “Methods” section) [61]
Gene Sanger sequencing of mosquito samples NGS of mosquito  samplesa Sequenced samples 
by both methods
p‑value
Wild type % Mutant % Mixture % Wild type % Mutant %
K13
 Y493H R539T I543T C580Y 100 0 0 100 0 66 1
pfcrt
 CVMNK (72–76) 100 0 0 100 0 93 1
pfmdr1 F1
 N86Y/F 98.8 0 1.2 100 0 81 3.44 × 10−4
 Y184F 46.9 21.0 32.1 50.3 49.3 0.59
pfmdr1 F2
 S1034C N1042D D1246Y 100 0 0 100 0 70 1
pfdhps F1
 S436F/A 100 0 0 100 0 86 1
 A437G 2.3 95.3 2.3 0 100 1.32 × 10−7
pfdhps F2
 K540E 2.3 96.6 1.1 6.2 93.7 87 0.17
A581G A613T/S 100 0 0 100 0 1
pfdhfr
 C50R/S 99 1.0 0 100 0 95 1.64 × 10−4
 N51I 0 100 0 0.9 98.4 1
 C59R 3.2 32.6 64.2 3.6 96.3 1
 S108N 0 100 0 0.3 96.3 1
 164L 100 0 0 100 0 1
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one sample each. However, position T1069T has been 
previously reported [23] and showed the same mutation 
along 4 mosquito samples, which could maybe indicate a 
plausible novel mutation. On a different note, SP resist-
ance linked to mutations in the pfdhps and pfdhfr genes 
in Africa is widespread [9]. In the study area, quintuple 
mutations of pfdhps and pfdhfr were nearly fixed. Yet, 
positions C50R/S and I164L of pfdhfr and S436F/A, 
A581G and A613T/S of pfdhps still remain wild-type 
according to results of both methods. Although it has 
been observed that pfdhfr polymorphism frequencies in 
mosquitoes may differ from those in humans [59], over-
all, our observations are within a similar range to those 
numbers obtained from human blood samples in other 
studies [60].
Sanger sequencing and NGS approaches gave overall 
very similar resistance markers estimates, in spite of some 
minor discrepancies. As previously mentioned, some of 
these discrepancies are due to the fact that Sanger will 
provide with prevalence approximations while NGS will 
measure allele frequency. While prevalence of resistance 
on a human subject level may inform treatment choice, 
on an epidemiological level the parameter of interest is 
allele frequency. Furthermore, frequency estimates also 
allow to capture minority emerging genotypes in mixed 
infections, which would be missed with prevalence analy-
ses that do not detect mixed alleles below a threshold 
of 10–20% [3, 60, 61]. On the flipside, however, preva-
lence analysis would be more sensitive for the detection 
of mutants that are at a higher frequency within a given 
sample but at low frequency on a population level. The 
latter, however, would be less likely to occur for novel 
emerging mutations. The NGS approach allows for pool-
ing of samples too, which reduces cost and performance 
time without compromise in information since the objec-
tive is population-level allele frequency [3]. Moreover, 
pooled deep sequencing offers high read coverage and 
sequencing depth and permits to increase sample size, 
as previously seen in other studies [3, 26, 27]. It also pro-
vides the means to monitor whole genes, which is neces-
sary for those with multiple point mutations associated 
with resistance and which would allow the detection of 
novel SNPs usually not analysed with other detection 
techniques. Moreover, results from this study show that 
pooled deep sequencing of infected mosquito samples is 
a more suitable alternative to pooled human blood sam-
ples deep sequencing. It does not require specialized per-
sonnel to draw blood from patients and it avoids complex 
ethical requirements and visiting expeditions, which can 
sometimes be very challenging in low-income settings. 
Since data obtained from mosquitoes has been shown 
to correlate well with data from humans [23, 36, 39, 60], 
mosquitoes could be used as a sentinel group for resist-
ance surveillance purposes.
A relatively high P. falciparum infection rate (23.6%) 
was observed in these mosquitoes collected in southern 
Mozambique, an area with high level of malaria transmis-
sion (between 100 and 200 cases per 1000 population) 
[29]. Of note however, was that extracts from head/tho-
rax (6%) and abdomen (18.3%) were for unclear reasons 
significantly lower than isolates from whole mosquitoes. 
Further studies are also needed to confirm if only abdo-
mens should be screened as according to our results they 
presented a higher positivity rate. However, it should be 
taken into account that there is the possibility to a change 
in allele proportions between head/thorax and abdomen 
portions. Nevertheless, as mentioned beforehand, for 
allele frequency purposes, however, a pooling strategy 
of whole mosquitoes would be adequate, such as previ-
ously demonstrated for the detection of dengue [62] and 
Ross River viruses [63], though with the limitation that 
any pooling strategy could bias results towards higher 
density infections. Interestingly, more P. falciparum posi-
tive mosquitoes appeared to be captured by miniature 
light traps than early morning collections using manual 
aspiration (Table 1). An intriguing hypothesis is that this 
could be due to behavioural manipulation: it is thought 
that Plasmodium-infected humans present an increased 
attractiveness to the arthropod vector [64] and that 
those mosquitoes infected with P. falciparum are more 
attracted to humans [65]. Moreover, it has explicitly been 
shown that Aedes aegypti infectious with Plasmodium 
gallinaceum present an increased host-seeking behaviour 
[66]. Because miniature light traps are located in close 
proximity to people sleeping under LLINs, this could 
explain the higher frequency of P. falciparum positive 
mosquitoes captured by the miniature light traps.
Although the proposed surveillance tool of NGS of P. 
falciparum isolates from mosquitoes is promising, there 
are some caveats. First, the validity of extrapolation of 
resistance marker frequency in mosquitoes to human 
population needs to be confirmed. Detection of resist-
ance markers could be more sensitive in the human 
host—when de novo mutants could have been selected—
instead of during the mosquito life cycle, when negative 
selection against mutants could occur. However, evidence 
for this effect is sparse (reviewed in [67]). Of note is that 
frequency of resistance surveillance in the mosquito vec-
tor is arguably a more relevant measure of resistance epi-
demiology as anti-malarial resistance is more likely to be 
transmitted than acquired (reviewed in [68]). Second, 
this study is based on a single mosquito species, Anophe-
les funestus, an indoor-biting highly antropophylic vector, 
and the extent to which different vector species carry dif-
ferent P. falciparum genotypes, and hence bias the allele 
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frequency, is unknown. However, it has been observed 
that different Plasmodium genotypes are randomly dis-
tributed [69]. Third, these mosquitoes were collected in 
a relatively high transmission area. The approach may be 
less cost-effective in a low transmission area when a larger 
number of mosquitoes need to be screened and NGS will 
be less capable of detecting low-density infections. How-
ever, this is a general issue for resistance surveillance in 
low transmission areas, irrespective of using human or 
mosquito samples. Pooled screening approaches would 
significantly reduce this cost to more efficiently identify P. 
falciparum infected specimens with the caveat that pool-
ing could bias results to high density mosquito samples. 
Fourth, as with many molecular approaches, this Illumina 
sequencing approach only allows the detection of known 
SNPs. Other approaches will be needed to detect novel 
mutations and gene duplications. Finally, NGS is a rela-
tively new technique linked to uncertainty due to errors 
in alignment, base calling or filtering [50]. For example, 
unexpected mutations in positions S436F/A, A437G, 
A581G and A613T/S of pfdhps in the 3D7 control were 
found (see Additional file  1: Table  S6) and statistically 
significant differences among Sanger and NGS results 
in pfmdr1 position N86Y/F, pfdhps position A437G and 
pfdhfr position C50R/S. These statistically significant 
differences could possibly be overcome by moving to an 
individual NGS approach rather than a pooled one. How-
ever, they could still be either a false negative or positive 
by Sanger sequencing or by NGS or a distinction between 
prevalence and frequency. It is, therefore, imperative 
to account for uncertainty linked to NGS and to try to 
reduce it. There are different strategies to do so, although 
one must accept that there is not a perfect combination 
and that the fast development of bioinformatic tools 
means that recommendations may change very rapidly 
but also improve [50].
Conclusions
In conclusion, pooled deep sequencing of P. falcipa-
rum isolates extracted from dried mosquitoes appears 
to be an efficient and cost-effective method to quantify 
allele frequencies at a population level. It is a promising 
technique, which allows not only to analyse known and 
unknown markers of resistance, but to detect them in 
mixed infections. Moreover, it allows to follow up rapid 
and radical population changes in a timelier manner 
as mosquitoes could be collected throughout the year 
and without a long planning phase of obtaining ethical 
approval. Therefore, this approach would allow active 
surveillance in an increasing number of sites in order 
to obtain information on molecular markers of resist-
ance, which could be applied to current malaria control 
programmes.
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